Amisulpride injection is used to prevent and treat nausea and vomiting that may occur
The recommended dosage of amisulpride:
Amisulpride (Injection
Amisulpride is said to be an "atypical" antipsychotic which induces less
Last updated on Sep 7, 2023
1 to 13
0 tablets) uses, composition, side-effects, price, substitutes, drug interactions, precautions, warnings, expert advice and buy online at best price on 1mg
You Background: Two essentially identical, randomized, double-blind, placebo-controlled, parallel-group phase III studies evaluated the efficacy of intravenous amisulpride, a dopamine D2/D3 antagonist, in the prevention of postoperative nausea and vomiting in adult surgical patients
BARHEMSYS (amisulpride) bah - rem’ - sis Were there any differences in how well the drug worked in clinical trials among sex, race, and age? Subgroup analyses were conducted for sex, race Amisulpride can be administered once daily at oral doses up to 300 mg, higher doses should be administered bid
A systematic review and combined meta-analysis of concentration of oral amisulpride
Amisulpride, a first-line schizophrenia treatment, has shown large interindividual variability in plasma/serum levels, often outside the reference range (100-320 ng/mL)
Patients were randomized to receive either intravenous amisulpride (5 mg) or matching placebo at induction of general anesthesia, in addition to one standard, nondopaminergic antiemetic, most commonly ondansetron or dexamethasone
This review addresses the potential of amisulpride analogs, particularly SEP-4199, in addressing these challenges through enhanced
We examined the effect of augmentation of oral low doses of amisulpride with lorazepam on resolution of catatonic symptoms
Economic analyses indicated that amisulpride augmentation has the potential to be cost-effective in the short term [net saving of between £329 and £2011; no difference in quality-adjusted life-years (QALYs)] and possibly in the longer term
Amisulpride was among the most efficacious antipsychotics, but no placebo-controlled study was available, making this evidence entirely indirect
78; 95% CI, -1
Results: We included 75 studies with 16 555 participants
Amisulpride has one of the lowest potentials for weight gain of all the antipsychotic agents, and is associated with clearly lower use of antiparkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics
The second trial (Study SEP380-201) was a randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study designed to evaluate the efficacy, safety, and tolerability of treatment